Haby Michelle M, Donnelly Marie, Corry Justine, Vos Theo
Health Surveillance and Evaluation Section, Public Health Group, Department of Human Services, Melbourne, Victoria, Australia.
Aust N Z J Psychiatry. 2006 Jan;40(1):9-19. doi: 10.1080/j.1440-1614.2006.01736.x.
To determine which factors impact on the efficacy of cognitive behavioural therapy (CBT) for depression and anxiety. Factors considered include those related to clinical practice: disorder, treatment type, duration and intensity of treatment, mode of therapy, type and training of therapist and severity of patients. Factors related to the conduct of the trial were also considered, including: year of study, country of study, type of control group, language, number of patients and percentage of dropouts from the trial.
We used the technique of meta-analysis to determine an overall effect size (standardized mean difference calculated using Hedges' g) and meta-regression to determine the factors that impact on this effect size. We included randomized controlled trials with a wait list, pill placebo or attention/psychological placebo control group. Study participants had to be 18 years or older and all have diagnosed depression, panic disorder (with or without agoraphobia) or generalized anxiety disorder (GAD). Outcomes of interest included symptom, functioning and health-related quality of life measures, reported as continuous variables at post-treatment.
Cognitive behavioural therapy for depression, panic disorder and GAD had an effect size of 0.68 (95% CI=0.51-0.84, n=33 studies, 52 comparisons). The heterogeneity in the effect sizes was fully explained by treatment, duration of therapy, inclusion of severe patients in the trial, year of study, country of study, control group, language and number of dropouts from the control group. Disorder was not a significant predictor of the effect size.
Cognitive behavioural therapy is significantly less effective for severe patients and trials that compared CBT to a wait-list control group found significantly larger effect sizes than those comparing CBT to an attention placebo, but not to a pill placebo. Further research is needed to determine whether CBT is effective when provided by others than psychologists and whether it is effective for non-English-speaking patient groups.
确定哪些因素会影响认知行为疗法(CBT)治疗抑郁症和焦虑症的疗效。所考虑的因素包括与临床实践相关的因素:疾病、治疗类型、治疗持续时间和强度、治疗模式、治疗师类型和培训以及患者的严重程度。还考虑了与试验实施相关的因素,包括:研究年份、研究国家、对照组类型、语言、患者数量以及试验中的失访率。
我们采用荟萃分析技术来确定总体效应量(使用赫奇斯g计算标准化均数差),并通过元回归来确定影响该效应量的因素。我们纳入了设有等待名单、药物安慰剂或注意力/心理安慰剂对照组的随机对照试验。研究参与者必须年满18岁,且均被诊断患有抑郁症、惊恐障碍(伴或不伴有广场恐惧症)或广泛性焦虑症(GAD)。感兴趣的结局包括症状、功能以及与健康相关的生活质量指标,在治疗后作为连续变量报告。
认知行为疗法治疗抑郁症、惊恐障碍和广泛性焦虑症的效应量为0.68(95%CI = 0.51 - 0.84,n = 33项研究,52次比较)。效应量的异质性完全由治疗、治疗持续时间、试验中纳入严重患者、研究年份、研究国家、对照组、语言以及对照组的失访率所解释。疾病并非效应量的显著预测因素。
认知行为疗法对严重患者的疗效显著较低,并且将CBT与等待名单对照组进行比较的试验发现其效应量显著大于将CBT与注意力安慰剂对照组进行比较的试验,但与药物安慰剂对照组比较时并非如此。需要进一步研究以确定由心理学家以外的人员提供CBT时是否有效,以及对非英语患者群体是否有效。